SAL 0114
Alternative Names: SAL-0114Latest Information Update: 15 Jul 2022
At a glance
- Originator Shenzhen Salubris Pharmaceuticals
- Class Antidepressants; Behavioural disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Agitation; Depressive disorders
Most Recent Events
- 15 Jul 2022 Phase-I clinical trials in Agitation in China (unspecified route) before July 2022 (Shenzhen Salubris Pharmaceuticals pipeline, July 2022)
- 15 Jul 2022 Phase-I clinical trials in Depressive disorders in China (unspecified route) before July 2022 (Shenzhen Salubris Pharmaceuticals pipeline, July 2022)
- 04 Mar 2022 Preclinical trials in Agitation in China (unspecified route) before March 2022